SCHEDULE 13D/A: Wildcat Capital's Stake in Silexion Therapeutics Diluted to 1.3% Amid Increased Outstanding Shares
Schedule 13D Amendment
Wildcat Capital Management, LLC and its affiliates have reported a decreased beneficial ownership percentage in Silexion Therapeutics Corp to 1.3% due to an increase in the issuer's outstanding ordinary shares.
Summary
- Wildcat Capital Management, LLC, Wildcat Partner Holdings, LP, and Leonard A. Potter collectively beneficially own 113,428 ordinary shares of Silexion Therapeutics Corp.
- This ownership represents 1.3% of Silexion Therapeutics Corp's ordinary shares outstanding.
- The percentage of beneficial ownership has decreased from a prior, unspecified level due to an increase in the total number of Silexion Therapeutics Corp's outstanding ordinary shares.
- As of May 30, 2025, Silexion Therapeutics Corp had 8,692,392 ordinary shares outstanding, as reported in its Proxy Statement on Schedule 14A filed on June 16, 2025.
- The filing is an Amendment No. 1 to the initial Schedule 13D filed on August 22, 2024, primarily to reflect the updated beneficial ownership percentage.
Sentiment
Score: 3
Explanation: The sentiment is moderately negative as the reporting person's stake has been diluted due to an increase in the issuer's outstanding shares, which typically reduces the value of existing holdings proportionally.
Negatives
- The beneficial ownership percentage of Wildcat Capital and its affiliates in Silexion Therapeutics Corp has decreased to 1.3% due to an increase in the issuer's outstanding shares, indicating dilution for existing shareholders.
Risks
- Shareholder dilution: The increase in the number of outstanding ordinary shares of Silexion Therapeutics Corp reduces the proportional ownership stake of existing shareholders, including Wildcat Capital and its affiliates.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Silexion Therapeutics Corp's future operations or financial performance.
Industry Context
This filing is a routine disclosure of a change in beneficial ownership percentage for a significant shareholder, reflecting the impact of share dilution on their stake. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The increase in outstanding shares results in dilution, reducing the proportional ownership and potential voting power of existing shareholders, including Wildcat Capital and its affiliates.
Key Dates
| Date | Description |
|---|---|
| 2024-08-22 | Initial Schedule 13D filed by Wildcat Capital Management, LLC. |
| 2025-01-17 | Date of event for Item 5(e) related to interest in securities. |
| 2025-05-30 | Date as of which 8,692,392 ordinary shares of Silexion Therapeutics Corp were outstanding. |
| 2025-06-16 | Silexion Therapeutics Corp filed its Proxy Statement on Schedule 14A with the SEC, reporting outstanding shares. |
| 2025-06-26 | Date of event requiring the filing of this Amendment No. 1 to Schedule 13D and the filing date of the amendment. |
Keywords
Silexion Therapeutics Corp, Wildcat Capital Management, Schedule 13D, beneficial ownership, share dilution, ordinary shares, SEC filing, investment management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.